

## North Central London Joint Formulary Committee

# **Ulcerative Colitis Prescribing Pathway**

### **Document control**

Date	Version	Amendments	
Nov 2023	3.0	Pathway developed in accordance with NCL 'Principles for Commissioning High-Cost Dr Pathways for ICB Commissioned Indications' and includes relevant published NICE TAs.	

	F
Groups / Individuals who have overseen the development of this guidance:	UCLH Lead Pharmacist, Formulary & Clinical Trials, UCLH Specialised Commissioning Lead Pharmacist, NCL ICB Medicines Management Team, NCL Joint Formulary Principal Pharmacist, NCL Specialist Clinicians
Groups which were consulted and have given approval:	NCL wide consultation (NCL ICB, NCL Formulary Pharmacists, NCL Specialist Clinicians), NCL Joint Formulary Committee (Nov 2023), NCL Integrated Medicines Optimisation Board (Nov 2023)
File name:	Ulcerative Colitis Prescribing Pathway
Version number:	3.0
Available on:	
Disseminated to:	NCL Joint Formulary Committee, NCL Formulary Pharmacists, NCL Commissioners, NCL Specialist Clinicians
Equality impact assessment:	Low risk
NCL JFC Approval date:	November 2023
Review date:	November 2026 (or sooner if updates required e.g. NICE TAs)

#### Disclaimer

This guideline is registered at North Central London (NCL) Joint Formulary Committee (JFC) and is intended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, clinical guidelines are for guidance only, their interpretation and application remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the manufacturer's current prescribing information before treating individual patients.

The authors and NCL JFC accept no liability for use of this information beyond its intended use.


While we have tried to compile accurate information in this guideline, and to keep it updated in a timely manner, we cannot guarantee that it is fully complete and correct at all times. If you identify information within this guideline that is inaccurate, please report this to the <u>admin.ncl-mon@nhs.net</u>. If a patient is harmed as a consequence of following this guideline, please complete a local incident report and inform <u>admin.ncl-mon@nhs.net</u>.

This guideline should not be to used or reproduced for commercial or marketing purposes.

NCL JFC is funded by and provides advice to Acute Trusts and the Integrated Care Board in NCL.

## **Ulcerative Colitis (UC) Prescribing Pathway**

Green: preferred best value Amber: not preferred (use where green not suitable) Red: not preferred (least cost-effective, use where green and amber not suitable)



Golimumab (not preferred) <sup>3</sup>	£££	<80Kg: 50mg SC every 4 weeks ≥80Kg: 100mg SC every 4 weeks	Not available
Tofacitinib <sup>4</sup>	££	5mg oral twice daily	Only if not at increased risk of VTE, MACE or malignancy: 10mg oral twice daily
(not preferred)			for the shortest duration possible

Assessment of response - Assess initial induction and/or dose escalation response in 12-22 weeks based on clinical symptoms and biological markers +/- endoscopy and imaging. If partial response, consider dose escalation. If no response, stop biologic and consider initiating alternative drug, surgery, or a clinical trial.

**Continuation of Biologic Treatment** - Treat for 12 months or until treatment failure (including the need for surgery), whichever is shorter, then review and discuss the risks and benefits of continued treatment or continued dose escalation. Continue only if there is evidence of response as determined by clinical symptoms, biological markers and investigation, including endoscopy if necessary. Reassess at least every 12 months to determine whether ongoing treatment is still clinically appropriate. Consider a trial of withdrawal for patients who are in stable clinical remission. If disease relapses after treatment is stopped patients have the option to start treatment again.

Adverse drug reactions (ADRs) – For patients who experience an immediate ADR [within 1 month] or have responded to treatment but experience an ADR within 6 months of treatment initiation, another treatment option within the same mechanism of action (if available and appropriate) can be accessed. Where the ADR is likely to be a drug class effect, an alternative mechanism of action is preferable.

**Dual biologic therapy for the same disease** is not routinely commissioned; for individual cases, please consider <u>RMOC advisory</u> <u>statement</u>, discuss at MDT and contact Trust formulary teams for advice re IFR submission. **Concurrent biologic treatment for different co-morbidities**, is permissible provided NICE eligibility criteria for both treatments are met and there is MDT agreement across both specialities that dual therapy is appropriate and a single drug which is active against both co-morbidities is not available.

#### Footnote

<sup>1</sup> The requirement for pre-treatment corticosteroids *or (rather than and)* azathioprine/6-mercaptopurine brings eligibility criteria consistency between TNF inhibitors (TA329) and other NICE TA'd medicines. Further, it brings consistency with Crohn's disease pathway [JFC Nov 2023].

<sup>2</sup> Whilst TA163 described that infliximab is recommended in patients in whom ciclosporin is contraindicated or clinically inappropriate, clinical practice has changed since 2008 and ciclosporin is not routinely offered because of adverse effect profile (inc. renal dysfunction and risk of serious infection), and the significant reduction in cost of infliximab given availability of biosimilars [JFC Nov 2023].

<sup>3</sup> Golimumab is the only treatment option recommended in TA329 which is not available as a biosimilar. By inference, it is not as costeffective as adalimumab and infliximab. As routine commissioning is for 'Up to one drug per mechanism of action, plus a second biosimilar TNF inhibitor', requests for golimumab should be via IFR and reserved for immunogenic loss of response to adalimumab and infliximab.

<sup>4</sup> Tofacitinib is more expensive and similarly effective as filgotinib (<u>TA792, Paragraph 3.8</u>), therefore not preferred.

<sup>5</sup> Upadacitinib may be offered to patients with primary non-response to filgotinib or tofacitinib, assessed as partial or no response at the 12-16 week assessment [JFC Nov 2023].

#### References

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults 2019

European Crohn's and Colitis Organisation Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment